June 4, 2020 -- Elixirgen Therapeutics said it has finished a preinvestigational new drug meeting with the U.S. Food and Drug Administration for its EXG-5003 COVID-19 vaccine candidate.
EXG-5003 is a temperature-sensitive, intradermally-injected self-replicating RNA (srRNA) vaccine that expresses the receptor binding domain of the SARS-CoV-2 spike protein, according to the company. Elixirgen believes that the vaccine candidate has unique features that potentially could provide dose sparing and safety benefits.
The combination of intradermal injection and srRNA technology may yield improved immunogenicity and may enable EXG-5003 to be more dose sparing than messenger RNA alone. In addition, its temperature sensitivity may enhance its safety profile, according to Elixirgen.
Copyright © 2020 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
